MUMBAI / RAJKOT - In a regulatory filing as submitted to the Indian Stock Exchanges, Mumbai headquartered pharmaceutical products manufacturing Lasa Supergenerics Ltd said of having realized success with Institute of Chemical Technolgy, for drug synthesis of antiviral drug Favipiravir which is used to treat COVID19 and that company shall commence production having got success on same drug development.
COVID 19: ICT, Lasa realise success in Favipiravir drug synthesis, to
commence production
API Major, Lasa Supergenerics and Institute of Chemical Technology had
come together in the month of March 2020 in effort to bring the antiviral to the market as a
promising therapy to fight the ongoing Covid-19 pandemic.
Favipiravir is an antiviral drug and is a promising antidote for the treatment of
Coronavirus disease (COVID-2019).
It possesses activity against many RNA viruses.
It is a guanine
analogue approved for influenza treatment.
It can effectively inhibit the RNA-dependent RNA
polymerase of RNA viruses such as influenza, Ebola, yellow fever, chikungunya, norovirus and
enterovirus, and a recent study reported its activity against 2019-nCoV.
Institute of Chemical Technology (ICT) Formerly the University Department of Chemical
Technology (UDCT) is a Public deemed University specialized in Chemical Technology located in
Mumbai, India.
It is focused in training and research in various branches of chemical engineering,
chemical technology and pharmacy.
No comments:
Post a Comment